Angiochem Validates its EPiC Technology via Rare Disease Deal with GSK
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 3 (Table of Contents)
Published: 12 Mar-2012
DOI: 10.3833/pdr.v2012.i3.1697 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
GlaxoSmithKline (GSK) has partnered with Angiochem to discover, develop and commercialise drugs for lysosomal storage diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS